![]() The data are significant and some patients who received pembrolizumab remain in treatment-free remissions, Raez concludes. However, the utility of pembrolizumab in patients with metastatic NSCLC is dependent on PD-L1 expression, Raez explains. Adverse events of any grade were less frequent in the. At 6 months, 80.2 of people in the pembrolizumab group were still alive compared with 72.4 of people in the chemotherapy group. This is important because less than 5% of this patient population could be cured only 20 years ago, but the 5-year survival data from KEYNOTE-024 showthe number has drastically increased. Patients who received pembrolizumab had longer median progression-free survival than patients who received chemotherapy, 10.3 months versus 6.0 months. Kim, Jin Zhang, Margaret Marie Smith, Reshma A. Now, 5-year survival have emerged, demonstrating clinically meaningful long-term overall survival benefit with the checkpoint inhibitor compared with chemotherapy, Raez says. KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1). The KEYNOTE-024 trial evaluated pembrolizumab (Keytruda) vs platinum-based chemotherapy regimens in patients with metastatic NSCLC. ![]() Raez, MD, FACP, FCCP, hematology and oncology, Medical Director, Chief Scientific Officer, Memorial Cancer Institute, Memorial Healthcare System, discusses the clinical implications of the phase 3 KEYNOTE-024 trial (NCT02142738) in non–small cell lung cancer (NSCLC). ![]()
0 Comments
Leave a Reply. |